Search research articles
Contact Us
Filters
Showing results (31-40 of 69) with videos related to
Page
of 7
Sort By:
NPJ Breast Cancer
|
November 30, 2022
Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT)
Tal Sella, Yue Zheng, Nabihah Tayob, et al.
Cancer Discovery
|
March 24, 2017
Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors
Dejan Juric, Ian Krop, Ramesh K Ramanathan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 24, 2013
Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors
Anne F Schott, Melissa D Landis, Gabriela Dontu, et al.
Future Oncology (London, England)
|
October 12, 2021
Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer
Ciara C O'Sullivan, Karla V Ballman, Linda McCall, et al.
JAMA Oncology
|
November 6, 2015
Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer
Chau Dang, Hao Guo, Julie Najita, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 7, 2014
Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline
Naren Ramakrishna, Sarah Temin, Sarat Chandarlapaty, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 7, 2014
Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline
Sharon H Giordano, Sarah Temin, Jeffrey J Kirshner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 2, 2012
Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors
Ian Krop, Tim Demuth, Tina Guthrie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 31, 2019
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer
Mothaffar F Rimawi, Polly Niravath, Tao Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 17, 2017
<sup>64</sup>Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer
Helen Lee, Anthony F Shields, Barry A Siegel, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 69) with videos related to
Sort By:
Page
of 7
NPJ Breast Cancer
|
November 30, 2022
Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT)
Tal Sella, Yue Zheng, Nabihah Tayob, et al.
Cancer Discovery
|
March 24, 2017
Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors
Dejan Juric, Ian Krop, Ramesh K Ramanathan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 24, 2013
Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors
Anne F Schott, Melissa D Landis, Gabriela Dontu, et al.
Future Oncology (London, England)
|
October 12, 2021
Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer
Ciara C O'Sullivan, Karla V Ballman, Linda McCall, et al.
JAMA Oncology
|
November 6, 2015
Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer
Chau Dang, Hao Guo, Julie Najita, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 7, 2014
Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline
Naren Ramakrishna, Sarah Temin, Sarat Chandarlapaty, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 7, 2014
Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline
Sharon H Giordano, Sarah Temin, Jeffrey J Kirshner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 2, 2012
Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors
Ian Krop, Tim Demuth, Tina Guthrie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 31, 2019
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer
Mothaffar F Rimawi, Polly Niravath, Tao Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 17, 2017
<sup>64</sup>Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer
Helen Lee, Anthony F Shields, Barry A Siegel, et al.
Page
of 7